Phoenix Life Sciences International Limited. (PLSI) 10-K 9 Apr 19 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Feb. 28, 2017	Feb. 28, 2019
Document and Entity Information:
Entity Registrant Name	Phoenix Life Sciences International Limited.
Document Type	10-K
Document Period End Date	Feb. 28, 2017
Trading Symbol	PLSI
Amendment Flag	false
Entity Central Index Key	0001493212
Current Fiscal Year End Date	--02-28
Well Known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Common Stock, Shares Outstanding		32,584,582
Entity Public Float		$ 70,032,000
Share price		$ 10.50
Entity Filer Category	Smaller Reporting Company
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2017

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Feb. 28, 2017	Feb. 29, 2016
ASSETS
Cash	$ 1,155	$ 7,591
Notes receivable, related party	235,752	249,352
Total Current Assets	236,907	256,943
Security deposit
Total Assets	236,907	256,943
Current Liabilities
Accounts payable and accrued liabilities	518,310	512,642
Due to related parties	277,219	267,219
Current Liabilities	795,529	779,861
Convertible notes payable, net	332,517	193,306
Derivative liability, Typenex note	471,437	397,512
Total Liabilities	1,599,483	1,370,679
STOCKHOLDERS' DEFICIT
Common Stock Authorized: 990,000,000 common shares, par value of $0.001 per share Issued and outstanding: 31,067 and 25,845 common shares, respectively	31	26
Additional paid-in capital	17,710,842	17,704,977
Accumulated deficit during the development stage	(19,073,749)	(18,819,039)
Total Stockholders' Equity	(1,362,576)	(1,113,736)
Total Liabilities and Stockholders' Equity	236,907	256,943
Preferred Series B [Member]
STOCKHOLDERS' DEFICIT
Issued and outstanding Preferred shares; Series B - 2,000,000; Series C - 995,600 and 998,000 respectively	200	200
Preferred Series C [Member]
STOCKHOLDERS' DEFICIT
Issued and outstanding Preferred shares; Series B - 2,000,000; Series C - 995,600 and 998,000 respectively	$ 100	$ 100

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Feb. 28, 2017	Feb. 29, 2016
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	990,000,000	990,000,000
Common stock, shares issued	31,067	25,845
Common stock, shares outstanding	31,067	25,845
Preferred Series B [Member]
Preferred stock, shares issued	2,000,000	2,000,000
Preferred stock, shares outstanding	2,000,000	2,000,000
Preferred Series C [Member]
Preferred stock, shares issued	995,600	998,000
Preferred stock, shares outstanding	995,600	998,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Feb. 28, 2017	Feb. 29, 2016
Income Statement [Abstract]
Revenues		$ 18,410
Cost of sales		5,933
Gross Profit		12,477
Operating expenses
Product development expense		120,604
Sales and marketing expenses		14,953
Operations expense		3,049
General and administrative	$ 4,006	33,613
Professional fees	31,805	329,975
Lease operating expenses		7,500
Total operating expenses	35,811	509,694
Loss before other expenses	(35,811)	(497,217)
Other income (expense)
Interest Income		4,031
Interest Expense	(136,775)	(173,763)
Loss on impairment of Inventory		(10,101)
Amortization of Discount on convertible notes payable	(2,435)	(10,435)
Gain (loss) on derivative liability	(79,689)	(227,644)
Gain (loss) on debt		127,310
Total other expense	(218,899)	(290,602)
Net loss	$ (254,710)	$ (787,819)
Basic and diluted loss per common share
Income (loss) from continuing operations (in dollars per share)	$ (8.63)	$ 0
Income (loss) from discontinued operations (in dollars per share)	0	0
Basic and diluted loss per common share (in dollars per share)	$ (8.63)	$ 0
Weighted average shares outstanding - basic and diluted (in shares)	29,509	273,479,547

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Deficit - USD ($)	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit during the Development Stage [Member]	Total
Balance, beginning at Feb. 28, 2015	$ 361,323		$ 17,247,631	$ (18,031,220)	$ (422,266)
Balance, beginning, shares at Feb. 28, 2015	361,322,812
Issuance of common stock for notes payable	$ 10,050		3,950		14,000
Issuance of common stock for notes payable (shares)	10,050,251
Issuance of common stock for true up of shares	$ 22,045		(22,045)
Issuance of common stock for true up of shares (in shares)	22,045,006
Issuance of common stock for notes payable	$ 30,509		(15,509)		15,000
Issuance of common stock for notes payable (shares)	30,509,190
Issuance of common stock for notes payable	$ 34,965		(9,965)		25,000
Issuance of common stock for notes payable (shares)	34,965,035
Reverse Split 1 for 10,000	$ (458,892)		458,892
Reverse Split 1 for 10,000 (shares)	(458,892,294)
Split	$ 46		(46)
Split (shares)	45,935
Issuance of common stock for notes payable	$ 4				4
Issuance of common stock for notes payable (shares)	4,236
Share cancellation	$ (27)		27
Share cancellation (shares)	(27,600)
Issuance of common stock	$ 2		1,941		1,943
Issuance of common stock (shares)	1,941
Share cancellation	$ (1)		1
Share cancellation (shares)	(667)
Issuance of common stock	$ 2		2,000		2,002
Issuance of common stock (shares)	2,000
Issuance of Preferred Stock Series B in exchange for common shares cancelled		$ 200	28,120		28,320
Issuance of Preferred Stock Series B in exchange for common shares cancelled (shares)		2,000,000
Issuance of Preferred Stock Series C in exchange for common shares cancelled		$ 100	10,000		10,100
Issuance of Preferred Stock Series C in exchange for common shares cancelled (shares)		1,000,000
Conversion of Preferred Stock Series C			(20)		(20)
Conversion of Preferred Stock Series C (shares)		(2,000)
Net loss for year				(787,819)	(787,819)
Balance, ending at Feb. 29, 2016	$ 26	$ 300	17,704,977	(18,819,039)	(1,113,736)
Balance, ending, shares at Feb. 29, 2016	25,845	2,998,000
Conversion of Preferred Stock Series C	$ 2		(2)
Conversion of Preferred Stock Series C (shares)	2,400	(2,400)
Issuance of common stock for warrant conversion	$ 3		5,867		5,870
Issuance of common stock for warrant conversion (in shares)	2,822
Net loss for year				(254,710)	(254,710)
Balance, ending at Feb. 28, 2017	$ 31	$ 300	$ 17,710,842	$ (19,073,749)	$ (1,362,576)
Balance, ending, shares at Feb. 28, 2017	31,067	2,995,600

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders' Deficit (Parenthetical) - shares	Feb. 28, 2017	Feb. 29, 2016
Preferred Series B [Member]
Conversion of shares		27,600
Preferred Series C [Member]
Conversion of shares	2,400	667
Preferred Series C [Member]
Conversion of shares	2,000
Preferred Stock [Member]
Conversion of shares		2,000
Common Stock [Member]
Conversion of shares	2,400	2,000
Common Stock [Member]
Conversion of shares	2,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Feb. 28, 2017	Feb. 29, 2016
Operating Activities
Net loss	$ (254,710)	$ (787,819)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash cost of impairment of license and distribution agreements		10,101
Non-cash amortization of discount on Typenex note	2,435	10,435
Non-cash loss on derivative on convertible notes	73,925	227,644
Non-cash interest expense on convertible notes payable	136,775
Debt conversion	5,870	(127,310)
Changes in operating assets and liabilities:
Accounts receivable		2,300
Security Deposit		1,250
Prepaid expenses and deposits		141,664
Accounts payable and accruals	15,669	293,937
Net Cash provided by (used for) operating activities - current operations	(20,036)	(227,798)
Investing Activities
Related party notes receivable	13,600	8,770
Net Cash provided by (used for) Investing Activities - continuing operations	13,600	8,770
Financing Activities
Due to related parties		217,219
Net Cash Provided By (used for) Financing Activities - continuing operations		217,219
Increase (Decrease) in Cash - continuing operations	(6,436)	(1,809)
Cash - Beginning of Period - continuing operations	7,591	9,400
Cash - End of Period - continuing operations	1,155	7,591
Supplemental disclosures
Income tax paid	15,789
Non-cash issuance of stock for conversion of debt	$ 5,870	$ 96,350

Nature of Operations and Contin

Nature of Operations and Continuance of Business	12 Months Ended
	Feb. 28, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Continuance of Business	1. Nature of Operations and Continuance of Business The company was incorporated in the State of Nevada on April 21, 2009 under the name Mokita Exploration, Ltd. (the “Company”). On February 27, 2014, there was a change of control of the Company. On February 28, 2014, the board of directors and a majority of holders of the Company’s voting securities approved a change of name of the Company to MediJane Holdings Inc. A Certificate of Amendment to effect the change of name was filed and became effective with the Nevada Secretary of State on March 4, 2014. A Certificate of Correction was subsequently filed with the Nevada Secretary of State on March 6, 2014 to correct a spelling error in the Company’s new name. These amendments have been reviewed by FINRA and were approved for filing with an effective date of March 12, 2014. The name change became effective with the Over-the-Counter Bulletin Board at the opening of trading on March 12, 2014 under our new ticker symbol “MJMD”. On March 8, 2017 the Company filed an Amendment to its Articles of Incorporation (the “Amendment”) with the Secretary of State of Nevada. As a result of the Amendment, the Company changed its name with the State of Nevada from Medijane Holdings, Inc. to Stem Bioscience, Inc. In May 2018 the Company again changed its name to Phoenix Life Sciences International Limited. A Certificate of Amendment to effect the change of name was filed and became effective with the Nevada Secretary of State on May 31, 2018. The name change was accepted by FINRA and became effective with the Over-the- Counter Bulletin Board on November 2, 2018 with the trading symbol “PLSI”. On February 27, 2014, after the change of control, the Company became a sales and distribution company focused on cannabinoid infused products for the treatment of medical conditions. On January 5, 2015, the Company underwent a change in control following the issuance of 276,000,000 common shares to Phoenix Bio Pharmaceuticals Corporation pursuant to a license agreement. On November 4, 2015, these shares were exchanged for 2,000,000 Series B Preferred Shares. The business was then changed to only focus on Cannabidiol (CBD) products. CBD is a non-psychotropic cannabinoid that is not restricted as part of the U.S. Controlled Substances Act (CSA), as defined under the 2014 U.S Farming Bill to be derivatives of the Industrial Hemp plant that contains less than 0.3% tetrahydrocannabinol (THC). The company may contract out the manufacturing of the products.. On October 10, 2018, the Company announced it had received approval from the Vanuatu Investment Promotion Authority (VIPA) to establish operations in the Republic of Vanuatu and manufacture botanical pharmaceutical products. Going Concern These financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company’s total operating expenditure plan for the following twelve months will require significant cash resources to meet the goals of its business plan. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Feb. 28, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation - Basis of Consolidation Use of Estimates - Other items subject to estimates and assumptions include the carrying amount of valuation of derivatives instruments and accrued liabilities, among others. Although management believes these estimates are reasonable, actual results could differ from these estimates. Cash and cash equivalents - Accounts receivable Basic and Diluted Net Loss per Share - Earnings per Share Financial Instruments - Fair Value Measurements and Disclosures Level 1 - Level 2 - Level 3 - The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, amounts due to related parties, and convertible debenture. Pursuant to ASC 820, the fair value of financial assets are determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations. Derivative Financial Instruments - The Company reviews the terms of the common stock, warrants and convertible debt it issues to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. The Company uses a Black-Scholes model for valuation of the derivative. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense, using the effective interest method. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether net cash settlement of the derivative instrument could be required within the 12 months of the balance sheet date. Comprehensive Loss - Comprehensive Income Stock-based Compensation - Compensation – Stock Based Compensation Equity-Based Payments to Non-Employees The fair value of each share based payment is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year: Risk-Free Interest Rate. Expected Volatility. Dividend Yield. Expected Term. Forfeitures. Revenue Recognition – The Company assesses the probability of collection based on a number of factors, including past transaction history with the customer and the current financial condition of the customer. If the Company determines that collection of a sale is not reasonably assured, revenue is deferred until the time collection becomes reasonably assured. Significant management judgment and estimates must be made and used in connection with the revenue recognized in any accounting period. Material differences may result in the amount and timing of our revenue for any period if our management made different judgments or utilized different estimates. Shipping and Handling costs – shipping and handling costs are included in cost of sales in the Statements of Operations. Recent Accounting Pronouncements – Reclassifications –

Variable Interest Entity

Variable Interest Entity	12 Months Ended
	Feb. 28, 2017
Variable Interest Entity
Variable Interest Entity	3. Variable Interest Entity The Company follows the guidelines in FASB Codification of ASC 810 “ Consolidation” - The reporting entity, its related parties, or both participated significantly in the design or redesign of the legal entity; - The legal entity is designed so that substantially all of its activities involve or are conducted on behalf of the reporting entity and its related parties; - The reporting entity and its related parties provide more than half of the total of the equity, subordinated debt, and other forms of subordinated financial support to the legal entity; or - The activities of the legal entity are primarily related to the securitizations or other forms of asset-backed financings or single-lessee leasing arrangements. A VIE is an entity that either (a) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (b) has equity investors who lack the characteristics of a controlling financial interest. A VIE is consolidated by its primary beneficiary. The primary beneficiary has both the power to direct the activities that most significantly impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the entity that could potentially be significant to the VIE. If we determine that we have operating power and the obligation to absorb losses or receive benefits, we consolidate the VIE as the primary beneficiary, and if not, we do not consolidate. The Company has not identified any VIEs as of February 28, 2017.

Intangible Assets

Intangible Assets	12 Months Ended
	Feb. 28, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	4. Intangible Assets Effective September 1, 2014, the Company changed its method of computing amortization from a sales percentage method to the straight-line method for the intangible assets. An assessment of useful life and / or discounted cash flow of the intangible asset is made and where the value is overstated the value is impaired.

Income Taxes

Income Taxes	12 Months Ended
	Feb. 28, 2017
Income Tax Disclosure [Abstract]
Income Taxes	5. Income Taxes The deferred tax assets or liabilities represent the future tax benefits or cost of those differences. The Company’s principal deferred tax items arise from net operating losses. Net operating losses approximate $19,100,000 which expire in the years 2030 through 2037. The net operating loss results in a deferred tax asset of $2,865,000. As future earnings are uncertain, the Company has provided a valuation allowance for the entire amount of the deferred tax asset. The Company is required to evaluate the tax positions taken in the course of preparing its tax returns to determine whether tax positions are “more likely than not” of being sustained by the applicable tax authority “More likely than not” is defined as greater than a 50% chance. The Company is delinquent on nearly all of its tax filings. As a result, there are presently no uncertain tax position and no reserves for uncertain tax positions. The Company has no unrecognized tax benefits at February 28, 2017 and February 29, 2016. The Company’s income tax returns are subject to examination by federal and state tax authorities. Due to the failure to file its tax returns, all prior tax years are open to examination. The Company recognizes interest and penalties associated with uncertain tax positions as part of the income tax provision and would include accrued interest and penalties with the related tax liability in the balance sheet. There were no interest and penalties paid or accrued during the years ended February 28, 2017 and February 29, 2016.

License Agreement - Phoenix Bio

License Agreement - Phoenix Bio Pharmaceuticals, Inc.	12 Months Ended
	Feb. 28, 2017
License Agreement - Phoenix Bio Pharmaceuticals Inc.
License Agreement - Phoenix Bio Pharmaceuticals, Inc.	6. License Agreement - Phoenix Bio Pharmaceuticals, Inc. On March 14, 2014, the Company entered into a License Agreement with Phoenix Bio Pharmaceuticals Corporation (“Phoenix Bio Pharm”) where Phoenix Bio Pharm has granted exclusive rights to the Company for North America to exploit all presently owned and after-acquired intellectual property rights and know-how of Phoenix Bio Pharm for certain medical cannabinoid products and delivery systems for the treatment and management of illnesses. The term of the License Agreement is Ten (10) years. In consideration of the acquired license, the Company issued 26,000,000 shares of common stock to Phoenix Bio Pharm, valued at $13,000,000 based on a discounted cash flow model and the fair value of the assets acquired in the license agreement. The Company will amortize the cost of the License Agreement over the ten year life. On January 5, 2015, the Company entered into an additional license agreement with Phoenix Bio Pharmaceuticals Corporation to expand the territories covered under its original license agreement dated March 14, 2014. Under the terms of the additional license agreement, the Company acquired the marketing rights to distribute products developed by Phoenix Bio Pharmaceuticals Corporation in Australia and New Zealand for ten years. In exchange for the license, the Company issued 250,000,000 restricted common shares at $0.016 per common share, for an aggregate value of $4,000,000. This amount represents 33% over the market value on the date of execution of the license agreement is $3,000,000. On July 8, 2015, the Company agreed to enter into a new licensing agreement with Phoenix Bio Pharmaceuticals Corporation. This new agreement shall replace the previous licensing agreements. The new licensing agreement shall be non-exclusive, CBD only licensing agreement with Phoenix Bio Pharmaceuticals Corporation. This license agreement operates for a twenty (20) year period. Phoenix Bio Pharm has granted to the Company a license for the territory of North America, Australia and New Zealand to exploit all presently owned and after-acquired intellectual property rights and know-how of Phoenix Bio Pharm related to CBD based cannabinoid products and delivery systems for the treatment and management of illnesses. Products falling under the license will include the following CBD products: transdermal patches, orally administered extracts, concentrated extracts of vaporizers and inhalers, sublingual and buccal dispensing products and extraction technology, suppository delivery systems, salves, creams, gels, lotions, and liquid extracts, and any product or active ingredients sourced through Phoenix Bio Pharm or third party suppliers or licensors. The Company will also have the right to sublicense the rights acquired pursuant to the license agreement and to use and develop copyrighted materials of Phoenix Bio Pharm for marketing and distribution purposes. In addition to the new licensing agreement, on July 8, 2015 the Company has entered into an exchange agreement with Phoenix Bio Pharm where all existing common shares held by Phoenix Bio Pharm (276,000,000) are exchanged for 2,000,000 Series B Preferred Shares, par value $0.0001. These preferred shares were entitled to 100 votes for each share held, and convertible into 100 common shares per preferred share at any time at the discretion of the holder. These preferred shares were cancelled on September 22, 2018. Subsequently as the Company has failed to meet projected cash flows which underpin the valuation model of the License Agreement, the Company determined that the balance of License Agreement should be impaired. Accordingly a total of $14,014,189 was expensed as an impairment to the License Agreement and paid in capital was reduced by $2,282,132 at year ended February 28, 2015.

Distribution Agreement - Go Kus

Distribution Agreement - Go Kush, Inc.	12 Months Ended
	Feb. 28, 2017
Distribution Agreement - Go Kush Inc.
Distribution Agreement - Go Kush, Inc.	7. Distribution Agreement – Go Kush, Inc. On May 13, 2014, the Company entered into a distribution agreement with GoKush.com (www.gokush.com) that is part of a not-for-profit California Cooperative Corporation that is dedicated to providing safe and legal access to medical marijuana for patients throughout California. Pursuant to the Agreement, amongst other things, GoKush agreed to become the online ordering platform for the ordering and re-stock of the Company’s products in California for a ten (10) year term and the Company has issued GoKush 200,000 shares of the Company’s restricted common stock valued at $172,000. The Company planned to amortize the cost of the Distribution Agreement over the ten year life beginning October 2014 when on-line sales of product commenced. However the Company was not paid for any sales and as such the Company determined that there is no value in the distribution agreement. Accordingly an impairment of $141,800 of the distribution agreement was made and paid-in capital was reduced by $13,000 at year ended February 28, 2015.

CV Sciences, Inc. FKA CannaVest

CV Sciences, Inc. FKA CannaVest Corp.	12 Months Ended
	Feb. 28, 2017
Debt Disclosure [Abstract]
CV Sciences, Inc. FKA CannaVest Corp.	8. CV Sciences, Inc. FKA CannaVest Corp. On December 23, 2014, the Company entered into a convertible promissory note for $1,200,000 with CannaVest Corp. The note represents $1,200,000 worth of raw material inventory to be obtained from CannaVest Corp. to use in the Company’s cannabidiol product formulations. The note accrues simple interest at a rate of 10% per annum and is due and payable in six months from the date of issue. The note cannot be prepaid. At any time, the outstanding principal amount of this note and all accrued but unpaid interest under this note can be converted into common shares at a price equal to the lesser of $0.02 per common share, the closing sale price, or the average of the lowest closing sale prices of the Company’s common shares during the five trading day period immediately preceding the date of such determination. Should the Company default on this convertible promissory note, all outstanding obligations payable by the Company are immediately due and payable. In addition, CannaVest Corp. may exercise any other right, power or remedy permitted by law. Further, upon even of default, all unpaid obligations under this note shall bear interest at the rate of 12% per annum. Warrant Agreement In connection with the convertible promissory note dated December 23, 2014, the Company subsequently issued warrants to purchase 20,000,000 common shares at an exercise price of $0.02 per common share to Kisha Spendthrift Trust, an affiliate of CannaVest Corp. These warrants were issued on January 6, 2015. In exchange for these warrants, the Company shall have access to the technical and management staff of CannaVest Corp. for the development of products to be manufactured from cannabidiol sourced from CannaVest Corp. The Company has valued these warrants using the black scholes option pricing model at $197,663 and will record the expense related to the warrants in its fourth fiscal quarter of 2014. On or about January 25, 2016, the Company entered into an Amendment No. 1 to the Convertible Promissory Note executed by and between the Company and CV Sciences, Inc (FKA Cannavest Corp. and referred to herein as “CVS”) dated December 23, 2014 (the “Note”), whereby the company and CVS agreed to terminate the Note upon the Company’s return of five containers of raw hemp oil to CVS. As of February 28, 2017 all remaining product had been returned to CVS, as the inventory did not meet quality standards and was returned for a reduction of the note balance. It was determined that the remaining inventory should be written off as at February 29, 2016.

Subsidiary Companies

Subsidiary Companies	12 Months Ended
	Feb. 28, 2017
Notes to Financial Statements
Subsidiary Companies	9. Subsidiary Companies On March 17, 2014, MediHoldings, Inc. (“MediHoldings”), a Colorado corporation, was formed as a wholly-owned subsidiary of the Company. On June 27, 2014, MediSales (CA), Inc. (“MediSales”), a California corporation, was formed as a wholly-owned subsidiary of the Company. Both these subsidiaries as at February 28, 2017 had not traded and were inactive.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Feb. 28, 2017
Related Party Transactions [Abstract]
Related Party Transactions	10. Related Party Transactions Martin Tindall Mr. Martin Tindall, assists the Company with business development activities through the Advisory Services Agreement with Kronos as discussed below. Mr. Tindall serves as the CEO of Kronos. Additionally, Mr. Tindall has provided new product development services through a New Product Development Agreement with Phoenix Pharms Capital Corporation, as discussed below. Mr. Tindall services as CFO and a Director of Phoenix Pharms Capital Corporation. Mr. Tindall also serves as a director of Phoenix Bio Pharmaceuticals Inc. Kronos International Investments Ltd. (“Kronos”) Sublease Agreement: Advisory Services Phoenix Bio Pharmaceuticals, Inc. (“Phoenix Bio Pharm”) Inventory Procurement Product Development Phoenix Pharms Capital Corporation (“Phoenix Pharms”) Related Party Loan: Russell Stone: Mr. Russell Stone, a Director of the Company, holds approximately 14% of the outstanding common shares of Phoenix Pharms Capital Corporation indirectly through a trust. Lewis “Spike” Humer Mr. Humer, a director of the Company, serves as CEO and a director of Phoenix Bio Pharmaceuticals and CEO and a director of Phoenix Pharms Capital Corporation. As of August 2014, the Company began paying Mr. Humer a consulting fee of $1,500 per week. As of February 28, 2015, the Company has paid Mr. Humer $19,000 and has accrued a related party payable to Mr. Humer of $27,000. During the year from March 1, 2015 to February 29, 2016, a further $81,000 was accrued to Mr. Humer. There were no further accruals from March 1, 2016 to February 28, 2017.

Common Stock

Common Stock	12 Months Ended
	Feb. 28, 2017
Common Stock
Common Stock	11. Common Stock The Company has authorized 990,000,000 shares of its common stock, $0.001 par value. On February 29, 2016, there were 24,845 shares of common stock issued and outstanding. On March 4, 2016, YP Holdings LLC converted 2,400 of the preferred shares to common shares which were issued by the Company. On September 15, 2016, the Company issued 2,822 shares of common stock to Typenex from the conversion of a total principal amount of $5,173 under a Warrant. As at February 28, 2017 there were 31,067 common shares on issue.

Preferred Stock

Preferred Stock	12 Months Ended
	Feb. 28, 2017
Preferred Stock
Preferred Stock	12. Preferred Stock On July 8, 2015, the Company approved the creation of four classes of preferred stock. - Series A preferred stock, par value $0.0001 par value, shall have 2,000,000 authorized shares. These preferred shares are not entitled to any voting rights and are convertible into common shares at the rate of $1.00 per common share at any time at the discretion of the holder Series A preferred shares rank senior to common shares and Series B preferred shares with respect to the right to receive dividends. - Series B preferred stock, par value $0.0001 par value, shall have 2,000,000 authorized shares. These preferred shares are entitled to 100 votes for each share held, and are convertible into 100 common shares at any time at the discretion of the holder. Series B preferred shares are senior to common shares. - Series C preferred shares, par value $0.0001 par value, shall have 2,000,000 authorized shares. These preferred shares are not entitled to any voting rights, and convertible into common shares at the rate of $1.00 per common share at any time at the discretion of the holder. Series C preferred shares are entitled to receive a preferred return equal to 10% of the gross cash sales income received in the ordinary course of business. Upon issue of the dividend, the value of such shares shall be deemed to be retired. Series C preferred shares rank senior to the common shares and Series B preferred shares with respect to the right to receive dividends - Series D preferred stock, par value $0.0001 par value, shall have 2,000,000 authorized shares. These preferred shares are not entitled to any voting rights, and can be converted into common shares at a rate of $1.00 per common share. Series D preferred shares are seen you two common shares and Series B preferred shares, and holders of Series D preferred shares are entitled to receive a preferred return equal to 10% of the gross cash sales income received in the ordinary course of business. Upon issue of the dividend, the value of such Series D preferred shares shall be deemed to be retired. On July 8, 2015, the Company approved the creation of four classes of preferred stock. - Series A preferred stock, par value $0.0001 par value, shall have 2,000,000 authorized shares. These preferred shares are not entitled to any voting rights and are convertible into common shares at the rate of $1.00 per common share at any time at the discretion of the holder Series A preferred shares rank senior to common shares and Series B preferred shares with respect to the right to receive dividends. - Series B preferred stock, par value $0.0001 par value, shall have 2,000,000 authorized shares. These preferred shares are entitled to 100 votes for each share held, and are convertible into 100 common shares at any time at the discretion of the holder. Series B preferred shares are senior to common shares. - Series C preferred shares, par value $0.0001 par value, shall have 2,000,000 authorized shares. These preferred shares are not entitled to any voting rights, and convertible into common shares at the rate of $1.00 per common share at any time at the discretion of the holder. Series C preferred shares are entitled to receive a preferred return equal to 10% of the gross cash sales income received in the ordinary course of business. Upon issue of the dividend, the value of such shares shall be deemed to be retired. Series C preferred shares rank senior to the common shares and Series B preferred shares with respect to the right to receive dividends - Series D preferred stock, par value $0.0001 par value, shall have 2,000,000 authorized shares. These preferred shares are not entitled to any voting rights, and can be converted into common shares at a rate of $1.00 per common share. Series D preferred shares are seen you two common shares and Series B preferred shares, and holders of Series D preferred shares are entitled to receive a preferred return equal to 10% of the gross cash sales income received in the ordinary course of business. Upon issue of the dividend, the value of such Series D preferred shares shall be deemed to be retired. On November 4, 2015, Phoenix Bio Pharmaceuticals Corporation were issued 2,000,000 Series B Preferred Shares in exchange for 27,600 common shares (27,600,000 pre-split). On February 18, 2016, YP Holdings, LLC was issued 1,000,000 Series B Preferred Shares in exchange for 667 common shares (6,666,667 pre-split). On February 28, 2016 YP Holdings, LLC converted 2,000 preferred shares into 2,000 common shares and on March 4, 2016, a further 2,400 preferred shares into common shares As at February 28, 2017, Phoenix Bio Pharmaceuticals Corporation owned 2,000,000 Series B Preferred Shares. YP Holdings, LLC owned 995,600 Series C Preferred Shares.

Common Stock Options

Common Stock Options	12 Months Ended
	Feb. 28, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Common Stock Options	13. Common Stock Options There were no common stock options on issue as at February 28, 2017.

Convertible Promissory Note

Convertible Promissory Note	12 Months Ended
	Feb. 28, 2017
Convertible Promissory Note
Convertible Promissory Note	14. Convertible Promissory Note On June 24, 2014, the Company entered into a securities purchase agreement with Typenex Co-Investment, LLC, a Utah limited liability company. Under this agreement, the Company has issued a secured convertible promissory note in the original principal amount of $1,105,000, deliverable in eleven tranches (the “Typenex Note”). On the closing date, Typenex delivered the initial cash purchase price of $150,000, plus any interest, costs, fees or charges accrued under the Typenex Note, including the original issue discount of $20,000. The outstanding principal and accrued and unpaid interest on the Typenex Note is convertible at any time into shares of common stock at a conversion price of $1.00, subject to adjustment as described below (the “Lender Conversion Price”). As of June 24, 2014, the Company evaluated the Beneficial Conversion Feature under this note and determined as of June 24, 2014, there was no beneficial conversion feature as the Lender Conversion Price exceeded the fair market value of the Company’s common stock. As of November 30, 2014, the company has received net proceeds of $135,000 related to this convertible promissory note, representing $150,000 less financing costs of $15,000. During the nine months ended November 30, 2014 the Company has recorded interest expense of $7,725, and amortization expense of $554,413 related to the amortization of the original issue discount and the full-value of the warrant discussed below ($552,500). Each subsequent tranche will be in the amount of $85,000, plus any interest, costs, fees or charges accrued thereon under the terms of the Typenex Note, including the original issuer discount of $8,500. Each tranche will be accompanied by its own secured investor note (the “Investor Notes”). The Company has agreed to pay $5,000 to cover Typenex’s legal fees, accounting costs, due diligence, monitoring and other transaction costs in connection with the purchase and sale of the Typenex Note. All loans received bear an interest rate of 10% per annum. The loan is due 23 months after the initial cash purchase price is delivered to the Company. Typenex has pledged a 40% membership interest in Typenex Medical, LLC to secure its obligations under all of the Typenex Notes. A warrant to purchase shares of the Company has been issued to Typenex as of June 24, 2014. This warrant grants Typenex the ability to purchase a number of fully paid and non-assessable shares of the Company’s stock, par value $0.001, equal to $552,500 divided by the market price. This warrant is issued pursuant to the terms of the securities purchase agreement as described above. Provided there is an outstanding balance, the Company will pay an installment amount equal to $61,388.89 plus any accrued and unpaid interest on the installment due date, which is six months after the initial loan disbursement. This installment amount is the maximum that must be paid on any given installment due date, and is limited by the amounts owed. This amount can be converted at the lesser of either the lender conversion price or at 70% of the average of the three lowest closing bid prices in the 20 trading days immediately preceding the applicable conversion. Should the average trading price be less than $0.35 during any such period, then the conversion factor will be reduced to 65% for all future conversion, additionally the conversion price will be reduced by 5% if the Company’s common stock is not available for DWAC. Should the Company decide to prepay this amount, there is a prepayment premium equal to 125% of the outstanding balance of the Typenex Note. Should the prepayment premium not be paid within 2 days of the prepayment notice, the Company forfeits its right to prepay the Typenex Note. Under this agreement, Typenex has the right at any time after the purchase price date until the outstanding balance has been paid in full to convert any or all of the outstanding balance into shares of the Company’s common stock under the following formula: the number of shares issued equals the amount being converted divided by $1. These shares must be delivered to Typenex within three trading days of the conversion notice being given to the Company. Should any shares be sold to Typenex or any third party at a value that is less than the effective lender conversion price, then the lender conversion price will be reduced to equal such lower issuance price. The effective lender conversion price will also be adjusted as needed upon any forward or reverse split of the Company’s shares. Should the Company fail to deliver the shares in a timely manner, a late fee of the greater of $500 per day and 2% of the applicable lender conversion share value rounded to the nearest multiple of $100 will be assed for each day after the third that the Company is late (though not exceeding 200% of the applicable lender conversion share value. In the event of a default, the Typenex Note may be accelerated by Typenex by providing written notice to the Company. The outstanding balance is immediately due and payable at the greater of the outstanding balance divided by the installment conversion price, or the default effect, which is calculated by multiplying the conversion eligible outstanding balance by 15% for each major default or 5% for each minor default and then adding the resulting product to the outstanding balance as of the date of default. In addition, an interest rate of the lesser of 22% per annum (or the maximum rate permitted under law) will be applied to the outstanding balance. Typenex is prohibited from owning more than 4.99% of the Company’s outstanding shares, unless the market capitalization of the Company’s common stock is less than $10,000,000, in which case Typenex is prohibited from owning more than 9.99% of the Company’s outstanding shares. On a date that is 23 trading days from each date that the Company delivers conversion shares to Typenex, there is a true-up date in which the Company will deliver additional shares if the installment conversion price on that date is less than the installment conversion price used in the applicable installment notice. These additional shares will be equal to the difference between the number of shares that would be delivered to Typenex at the time of the true-up date and the amount originally delivered.\ Notice of Default On February 3, 2015, the Company exercised its borrower offset right under the Typenex Note. Through this offset right, the Company is entitled to deduct and offset any amount owing by Typenex under the initial securities purchase agreement dated June 24, 2014 from any amount owed by the Company under the note. The combined balance of the secured investor notes and the investor notes as of the January 28, 2015 offset date was $890,800. In addition, the note balance prior to the offset included $85,000 of unearned original issue discounts. In conjunction with the Company’s exercise of its offset right, the Company and Typenex each hereby acknowledge that the secured investor notes and the investor notes were offset against the Company balances owed under the note as of the offset date, and as a result thereof, each of the secured investor notes and the investor notes is deemed to have been paid in full and are now cancelled and terminated and the Company balance owed under the note has been reduced to $218,028.47 as of the offset date. Additionally, the Company specifically acknowledges that Typenex has no further obligations under any of the secured investor notes and investor notes. Further, the Company acknowledges that the investor pledge agreement, dated June 24, 2014, and all security interests granted thereunder with respect to the collateral (as defined in the investor pledge agreement) have terminated and all such security interests shall be deemed released. Notice of Conversion Date of Notice Principal Market Price* Conversion Shares True Up Shares Total Shares Issued September 15, 2016 5,870 — 2,822 — 2,822

Subsequent Events

Subsequent Events	12 Months Ended
	Feb. 28, 2017
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events On March 8, 2017, the Company filed an Amendment to its Articles of Incorporation (the “Amendment”) with the Secretary of State of Nevada. As a result of the Amendment, the Company has changed its name with the State of Nevada from MediJane Holdings, Inc. to Stem Bioscience, Inc. On May 31, 2018, the Company filed an Amendment to its Articles of Incorporation (the “Amendment”) with the Secretary of State of Nevada. As a result of the Amendment, the Company has changed its name with the State of Nevada from Stem Bioscience, Inc. to Phoenix Life Science International Limited. Pursuant to the Agreement and Plan of Merger, dated as of September 18, 2018 as (The “Merger Plan” by and between Phoenix Life Sciences International Limited, a Nevada Corporation (the “Company”) and Phoenix Life Sciences International Limited, a Canadian Corporation (“PLSI CA”), the Company completed its merger with PLSI CA, with the Company as the surviving entity. On September 18, 2018, the Company’s Board of Directors announced the finalized consolidation activities of Phoenix Life Sciences International Limited with Stem Biosciences, Inc., Blue Dragon Ventures, and the MediJane Brand, and that the Company’s common stock would trade publicly under the symbol MJMD. On September 21, 2018, the Company announced it had obtained consent from the holder, Phoenix Bio Pharmaceuticals Corporation for the cancellation of 2,000,000 Preferred Series B shares in the Company in connection with the restructure of the Company and merger with Phoenix Life Sciences International Limited, a Canadian Corporation. On September 22, 2018, the Company’s Board of Directors accepted the resignation of Russell Stone from his position as a Director. On or about June 24, 2014, the Company entered into a Convertible Promissory Note with a face value of $1,105,000 (the “Note”) by and between the Company and Typenex Co-Investment, LLC (“Typenex”). On or about April 19, 2018, the Phoenix Life Sciences International Ltd, a Canadian Corporation (“PLSI CA”) acquired the entirety of the Notes outstanding principal and interest balance from Typenex. Upon the completion of the merger, that Note was conveyed to the Company. On September 22, 2018, the Company’s Board of Directors resolved to deem the acquired Notes principal balance satisfied, and to terminate the Note and any and all rights and obligations arising thereunder, including without limitation the cancellation of all Warrants issued to Typenex under the Note. On September 24, 2018, the Company issued 30,502,375 shares of common stock bearing the restricted legend without registration (the “Issued Shares”). Of these, 29,802,375 shares were issued in reliance on Rule 802 under the Securities Act in a 1:1 share exchange related to the merger of PLSI CA and the company as described above, and 700,000 shares were issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act. All of the Issued Shares were issued in private transactions, and the company received no proceeds from the Issued Shares. The Issued Shares, in conjunction with the 47,571 shares of common stock previously issued by the Company, brings the current issued and outstanding share count to 30,549,946. On October 3, 2018, the following persons were appointed to the Board of the Company, Stephen Cornford, Martin Tindall as Chief Executive Officer, Janelle Marsden as Managing Director and Geoffrey Boynton as Chief Financial Officer. Lewis “Spike” Humer stepped down from his executive role but remains a Director. On October 3, 2018, the Company agreed to issue 48,000 shares of restricted common stock to KHAOS Media Group as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act for services previously rendered and invoiced between March and December 2014. On November 2, 2018, FINRA confirmed the name change and change of symbol to “PLSI” On November 9, 2018, the Company announced that 2,000,000 Series C Preferred Stock had been cancelled and all convertible debt had been retired. There was no outstanding preferred stock on issue as at this day. On December 4, 2018, the Company issued 229,600 common shares as part of settlement agreements. On December 17, 2018, the Company issued 675,028 common shares which included 191,668 common shares as part of settlement agreements and 483,360 common shares issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act. On January 11, 2019, the Company issued 500,600 common shares to YP Holding, LLC. as part of a settlement agreement. On January 15, 2019 the Company issued 54,580 common shares which included 53,500 common shares as part of settlement agreements and 1,080 common shares issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act. On February 20, 2019 the Board of the Company appointed Michael Gobel, who has long and distinguished career in corporate finance in Australia, as a non-executive Director On February 26, 2019 the Company issued 315,928 common share which included 5,460 common shares as part of settlement agreements, 126,750 common shares issued as compensation for services rendered in reliance of Section 4(a)(2) of the Securities Act and 183,718 for cash consideration. On April 2, 2019 the Company issued 151,216 common share for cash consideration. Phoenix Life Sciences International Limited (Canada) and Phoenix Life Sciences International Limited (Nevada) commenced the consolidation of business in 2018. During that time, affiliates of the Company provided certain working capital and covering of costs related to the consolidation. Subsequently the Company has entered into subscription agreements with certain affiliates and key non-affiliate investors to provide a total of approximately USD $2.1million of financing. Shares of common stock issued for this total financing represent approximately 800,000. The key non-affiliate investor who had previously entered into a subscription agreement to purchase USD $20 million of shares at $10 per share with Phoenix Life Sciences International Limited Canada has entered into an agreement to exchange the subscription for warrants to purchase Company common stock at a price of $10, with the purchases to be completed by December 31, 2019. Further, as part of the merger and consolidation, Phoenix Life Sciences International Limited (Canada) and Phoenix Life Sciences International Limited (Nevada) entered into settlement agreements with former investors, employees and contractors whereby their debt, shares held in entities subject of the consolidation, or outstanding amounts were settled in exchange for a full release of claims and the Company issuing approximately eight (8) million shares and the assumption of approximately $2 million of settlements payable. The purpose of the consolidation, in addition to providing the deemed necessary relationships and contracts for the Company to execute on its strategy, was to settle any potential claim or liability to ensure that the Company was not subject to any claims by former investors, employees and contractors.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Feb. 28, 2017
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation -
Basis of Consolidation	Basis of Consolidation
Use of Estimates	Use of Estimates - Other items subject to estimates and assumptions include the carrying amount of valuation of derivatives instruments and accrued liabilities, among others. Although management believes these estimates are reasonable, actual results could differ from these estimates.
Cash and cash equivalents	Cash and cash equivalents -
Accounts Receivable	Accounts receivable
Basic and Diluted Net Loss per Share	Basic and Diluted Net Loss per Share - Earnings per Share
Financial Instruments	Financial Instruments - Fair Value Measurements and Disclosures Level 1 - Level 2 - Level 3 - The Company’s financial instruments consist principally of cash, accounts receivable, accounts payable and accrued liabilities, amounts due to related parties, and convertible debenture. Pursuant to ASC 820, the fair value of financial assets are determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.
Derivative Financial Instruments	Derivative Financial Instruments - The Company reviews the terms of the common stock, warrants and convertible debt it issues to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. The Company uses a Black-Scholes model for valuation of the derivative. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense, using the effective interest method. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether net cash settlement of the derivative instrument could be required within the 12 months of the balance sheet date.
Comprehensive Income	Comprehensive Loss - Comprehensive Income
Stock-based Compensation	Stock-based Compensation - Compensation – Stock Based Compensation Equity-Based Payments to Non-Employees The fair value of each share based payment is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year: Risk-Free Interest Rate. Expected Volatility. Dividend Yield. Expected Term. Forfeitures.
Revenue Recognition	Revenue Recognition – The Company assesses the probability of collection based on a number of factors, including past transaction history with the customer and the current financial condition of the customer. If the Company determines that collection of a sale is not reasonably assured, revenue is deferred until the time collection becomes reasonably assured. Significant management judgment and estimates must be made and used in connection with the revenue recognized in any accounting period. Material differences may result in the amount and timing of our revenue for any period if our management made different judgments or utilized different estimates.
Shipping and Handling Costs	Shipping and Handling costs
Recent Accounting Pronouncements	Recent Accounting Pronouncements –
Reclassifications	Reclassifications –

Convertible Promissory Note (Ta

Convertible Promissory Note (Tables)	12 Months Ended
	Feb. 28, 2017
Convertible Promissory Note
Schedule of conversion activity of debt	The table below lists the conversion activity and the shares of common stock issued pursuant to each conversion: Date of Notice Principal Market Price* Conversion Shares True Up Shares Total Shares Issued September 15, 2016 5,870 — 2,822 — 2,822

Nature of Operations and Cont_2

Nature of Operations and Continuance of Business (Details Narrative) - shares	Feb. 28, 2017	Nov. 04, 2016	Feb. 29, 2016	Nov. 04, 2015	Jan. 05, 2015
Common shares issued	31,067		25,845
Phoenix Bio Pharm [Member] | Additional License Agreement [Member]
Common shares issued					276,000,000
Phoenix Bio Pharm [Member] | Preferred Series B [Member]
Common shares issued		2,000,000		2,000,000

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Feb. 28, 2017USD ($)
Net operating losses	$ 19,100,000
Deferred tax asset net operating loss	$ 2,835,000
Minimum [Member]
Expiration Date	Dec. 31, 2037
Maximum [Member]
Expiration Date	Jan. 1, 2030

License Agreement - Phoenix B_2

License Agreement - Phoenix Bio Pharmaceuticals, Inc. (Details Narrative) - USD ($)	Jan. 05, 2015	Mar. 14, 2014	Mar. 13, 2014	Feb. 29, 2016	Feb. 28, 2015	Feb. 28, 2019	Jul. 08, 2015
Issuance price per share						$ 10.50
Preferred Series C [Member]
Issuance price per share							$ 1
Series A Preferred Stock [Member]
Issuance price per share							1
Series D Preferred Stock [Member]
Issuance price per share							$ 1
Distribution Agreement [Member]
Shares issued for agreement (shares)			200,000
Shares issued for agreement			$ 172,000
Useful life			10 years
Impairment of license agreement					$ 141,800
Reduction in paid in capital for impairment					13,000
Phoenix Bio Pharm [Member]
Term of the agreement				2 years
Common stock held by licensee							276,000,000
Phoenix Bio Pharm [Member] | Preferred Series B [Member]
Number of shares to be received in exchange for common stock held							2,000,000
Preferred stock, par value							$ 0.0001
Convertible preferred stock, conversion basis							100
Preferred return value of preferred shares							$ 100
Phoenix Bio Pharm [Member] | Additional License Agreement [Member]
Shares issued for agreement (shares)	250,000,000
Shares issued for agreement	$ 4,000,000
Term of the agreement	10 years
Useful life	10 years
Issuance price per share	$ 0.016
Value of stock issuance over market value of license agreement (percent)	33.00%
Impairment of license agreement					14,014,189
Reduction in paid in capital for impairment					$ 2,282,132
License Agreement	$ 3,000,000
Phoenix Bio Pharm [Member] | License Agreement [Member]
Shares issued for agreement (shares)		26,000,000
Shares issued for agreement		$ 13,000,000
Term of the agreement		10 years
Useful life		10 years

Distribution Agreement Go Kush,

Distribution Agreement Go Kush, Inc. (Details Narrative) - Distribution Agreement [Member] - USD ($)	Mar. 13, 2014	Feb. 28, 2015
Shares issued for agreement (shares)	200,000
Shares issued for agreement	$ 172,000
Term of agreement	10 years
Impairment of agreement		$ 141,800
Reduction in paid in capital for impairment		$ 13,000

CV Sciences, Inc. FKA CannaVe_2

CV Sciences, Inc. FKA CannaVest Corp. (Details Narrative) - USD ($)	2 Months Ended
	Feb. 29, 2016	Jan. 06, 2015	Dec. 23, 2014
Convertible Promissory Notes [Member]
Debt amount			$ 1,200,000
Interest rate			10.00%
Conversion price per common share			$ 0.02
Raw materials inventory to be acquired			$ 1,200,000
Default interest rate			12.00%
Warrant [Member]
Number of common shares for issued warrants		20,000,000
Exercise price		$ 0.02
Stockbased compensation expense	$ 197,663

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Sep. 18, 2014	Aug. 14, 2014	Jun. 30, 2015	Mar. 31, 2014	Feb. 28, 2017	Feb. 29, 2016	Feb. 28, 2015
Principal payments of related party loan						$ 217,219
Mr. Humer - CEO And Director [Member]
Monthly agreement payment		$ 1,500
Consulting fee							$ 19,000
Due to related party						81,000	27,000
Phoenix Pharms [Member] [Default Label]
Interest rate	8.00%
Loans made to related parties	$ 85,000
Due to related party							0
Due from related party loan					$ 39,892		61,262
Due from related party							2,687
Principal payments of related party loan							26,425
Cash payments of related party loan							15,900
Expense offset against related party loan							$ 10,525
Kronos [Member]
Lease term					4 years
Monthly rent expense					$ 2,500
Rent expenses					7,500
(Increase) Decrease in security deposit					1,250
Advisory service fees			$ 1,250	$ 10,000	$ 120,000	$ 120,000
Phoenix Bio Pharm [Member]
Term of the agreement						2 years
Loans made to related parties						$ 195,860
Product development expense						15,000
Phoenix Pharms [Member]
Due from related party loan						$ 52,492
Russell Stone - CEO [Member]
Ownership interest of Company						14.00%

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)	Sep. 15, 2016	Mar. 04, 2016	Feb. 28, 2017	Nov. 04, 2016	Feb. 29, 2016	Nov. 04, 2015
Common stock, par value (in dollars per share)			$ 0.001		$ 0.001
Common stock, shares authorized			990,000,000		990,000,000
Common stock, shares issued			31,067		25,845
Common stock, shares outstanding			31,067		25,845
Shares issued upon conversion of convertible debt (shares)	2,822
Prinicpal amount of debt converted	$ 5,173
Phoenix Bio Pharm [Member] | Preferred Series B [Member]
Common stock, shares issued				2,000,000		2,000,000
Convertible Promissory Notes [Member]
Shares issued upon conversion of convertible debt (shares)		2,400

Preferred Stock (Details Narrat

Preferred Stock (Details Narrative) - $ / shares	Feb. 28, 2017	Feb. 28, 2016	Feb. 18, 2016	Nov. 04, 2015	Jul. 08, 2015	Feb. 28, 2019	Feb. 29, 2016
Conversion price per share						$ 10.50
YP Holding, LLC [Member] | Common Stock [Member]
Number of preferred shares converted		2,000
Preferred Series B [Member]
Preferred stock, voting rights					100 votes for each share held
Preferred stock, issued	2,000,000						2,000,000
Number of preferred stock, owned	2,000,000
Preferred Series B [Member] | YP Holding, LLC [Member]
Number of preferred stock, pre-split			6,666,667
Preferred stock, issued			1,000,000
Number of preferred shares exchange			667
Preferred Series B [Member] | Phoenix Bio Pharm [Member]
Preferred stock, par value (in dollars per share)					$ 0.0001
Number of preferred stock, pre-split				27,600,000
Preferred stock, issued	2,000,000			2,000,000
Number of preferred shares exchange				27,600
Preferred Series C [Member]
Conversion price per share					$ 1
Percentage of preferred stock returns					10.00%
Preferred stock, issued	995,600						998,000
Preferred Series C [Member] | YP Holding, LLC [Member]
Preferred stock, issued	1,000,000
Number of preferred stock, owned	995,600
Series A Preferred Stock [Member]
Conversion price per share					$ 1
Series D Preferred Stock [Member]
Conversion price per share					$ 1
Percentage of preferred stock returns					10.00%

Convertible Promissory Note (De

Convertible Promissory Note (Details) - USD ($)	Sep. 15, 2016	Feb. 28, 2017
Debt principal amount	$ 5,173
Notice #1 [Member]
Date of Notice		Sep. 15, 2016
Debt principal amount		$ 5,870
Conversion Shares		2,822
Total Shares Issued		2,822

Convertible Promissory Note (_2

Convertible Promissory Note (Details Narrative)	Feb. 12, 2015USD ($)	Jun. 24, 2014USD ($)Number$ / shares	Nov. 30, 2014USD ($)	Feb. 28, 2019$ / shares	Feb. 28, 2017USD ($)	Feb. 29, 2016USD ($)	Jun. 24, 2015USD ($)	Jan. 28, 2015USD ($)	Jan. 23, 2015USD ($)shares	Jan. 09, 2015USD ($)	Dec. 16, 2014USD ($)	Sep. 17, 2014
Share price | $ / shares				$ 10.50
Derivative liability					$ 471,437	$ 397,512
Securities Agreement [Member] | Minimum [Member]
Ownership interest of Company												4.99%
Securities Agreement [Member] | Maximum [Member]
Ownership interest of Company												9.99%
Securities Agreement [Member] | Typenex Note [Member]
Debt amount		$ 1,105,000					$ 1,105,000	$ 890,800
Conversion price per common share | $ / shares		$ 1
Original issue discount		$ 20,000						85,000
Number of tranches | Number		11
Proceeds from notes payable			$ 150,000
Membership interest pledged		40.00%
Warrant issued fair value											$ 552,500
Debt installment amount		$ 61,389
Number of consecutive trading days		20 days
Conversion price equals average closing bid price (percent)		70.00%
Share price | $ / shares		$ 0.35
Conversion price reduction due to closing bid price (percent)		65.00%
Conversion price reduction due to availability of common stock (percent)		5.00%
Prepayment premium (percent)		125.00%
Late fee for failure to deliver shares		$ 500
Late fee applicable lender conversion share value (percent)		2.00%
Maximum late fee applicable lender conversion share value (percent)		200.00%
Default interest rate		22.00%
Major default rate of conversion eligible balance (percent)		15.00%
Minor default rate of conversion eligible balance (percent)		5.00%
Number of trading days from coversion date		23 days
Outstanding debt amount								$ 218,028
Amount of penalties waived	$ 26,755
Derivative liability											$ 230,932
Proceeds from notes payable, net			135,000
Financing costs			15,000
Interest expense - debt			7,725
Non-cash amortization of discount on convertible notes payable			$ 554,413
Costs payable under agreement		$ 5,000
Securities Agreement [Member] | Typenex Note [Member] | Minimum [Member]
Ownership interest of Company		4.99%
Market capitalization under agreement		$ 10,000,000
Securities Agreement [Member] | Typenex Note [Member] | Maximum [Member]
Ownership interest of Company		9.99%
Securities Agreement [Member] | Typenex Note [Member] | Notice #1 [Member]
Debt amount									$ (1,100,000)
Default penalty of outstanding balance (percent)										115.00%
Outstanding debt amount										$ 239,484
Common stock reserved for conversion of debt | shares									50,925,000
Securities Agreement [Member] | Typenex Note [Member] | Tranche [Member]
Debt amount		$ 85,000
Interest rate		10.00%
Original issue discount		$ 8,500
Debt term		23 months

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Apr. 02, 2019	Feb. 26, 2019	Jan. 15, 2019	Jan. 11, 2019	Dec. 17, 2018	Dec. 04, 2018	Nov. 09, 2018	Oct. 03, 2018	Sep. 24, 2018	Feb. 28, 2018	Sep. 22, 2018	Feb. 28, 2017	Feb. 29, 2016	Jun. 24, 2015	Jan. 28, 2015	Jun. 24, 2014	Feb. 28, 2014
Number of common stock, issued													361,322,812				63,000,000
Number of common stock, outstanding												31,067	25,845
Securities Agreement [Member] | Typenex Note [Member]
Debt amount														$ 1,105,000	$ 890,800	$ 1,105,000
Subsequent Event [Member]
Number of stock issued	151,216	315,928	54,580		675,028
Subsequent Event [Member] | Preferred Series C [Member]
Number of forfeited stock							2,000,000
Subsequent Event [Member] | KHAOS Media Group [Member] | Restricted Common Stock [Member]
Number of stock issued for services								48,000
Subsequent Event [Member] | Settlement Agreements [Member]
Number of stock issued		5,460	53,500		191,668	229,600
Number of stock issued for services		126,750	1,080		483,360
Number of stock issued, cash consideration		183,718
Subsequent Event [Member] | Settlement Agreements [Member] | YP Holding, LLC [Member]
Number of stock issued				500,600
Subsequent Event [Member] | Private Placement [Member] | Restricted Common Stock [Member]
Number of stock issued									30,502,375
Number of common stock, issued									30,549,946		47,571
Number of common stock, outstanding									30,549,946		47,571
Subsequent Event [Member] | Phoenix Life Sciences International Limited [Member]
Issuance of common stock for settlement agreement (shares)										8,000,000
Assumption of settlements payable in merger										$ 2,000,000
Subsequent Event [Member] | Phoenix Life Sciences International Limited [Member] | Subscription Agreement [Member]
Amount of financing to be provided										2,100,000
Sale of Stock, Consideration to be received per transaction										$ 20,000,000
Price per share										$ 10
Subsequent Event [Member] | Phoenix Life Sciences International Limited [Member] | Private Placement [Member] | Restricted Common Stock [Member]
Number of stock, issued, rule 802									29,802,375
Stockholder's equity, exchange ratio									1:1
Number of stock issued for services									700,000